Advertisement

Loading...

Avicanna Inc.

AVCN.TOTSX
Healthcare
Drug Manufacturers - Specialty & Generic
$0.15
$0.00(0.00%)
Canadian Market opens in 15h 2m

Avicanna Inc. Fundamental Analysis

Avicanna Inc. (AVCN.TO) shows moderate financial fundamentals with a PE ratio of -9.16, profit margin of -7.37%, and ROE of -68.32%. The company generates $0.0B in annual revenue with strong year-over-year growth of 51.62%.

Key Strengths

PEG Ratio0.84

Areas of Concern

ROE-68.32%
Operating Margin-12.55%
Cash Position2.70%
Current Ratio0.90
We analyze AVCN.TO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -29.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-29.3/100

We analyze AVCN.TO's fundamental strength across five key dimensions:

Efficiency Score

Weak

AVCN.TO struggles to generate sufficient returns from assets.

ROA > 10%
-8.87%

Valuation Score

Excellent

AVCN.TO trades at attractive valuation levels.

PE < 25
-9.16
PEG Ratio < 2
0.84

Growth Score

Excellent

AVCN.TO delivers strong and consistent growth momentum.

Revenue Growth > 5%
51.62%
EPS Growth > 10%
63.80%

Financial Health Score

Moderate

AVCN.TO shows balanced financial health with some risks.

Debt/Equity < 1
0.00
Current Ratio > 1
0.90

Profitability Score

Weak

AVCN.TO struggles to sustain strong margins.

ROE > 15%
-6832.28%
Net Margin ≥ 15%
-7.37%
Positive Free Cash Flow
No

Key Financial Metrics

Is AVCN.TO Expensive or Cheap?

P/E Ratio

AVCN.TO trades at -9.16 times earnings. This suggests potential undervaluation.

-9.16

PEG Ratio

When adjusting for growth, AVCN.TO's PEG of 0.84 indicates potential undervaluation.

0.84

Price to Book

The market values Avicanna Inc. at 5.53 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

5.53

EV/EBITDA

Enterprise value stands at -18.46 times EBITDA. This is generally considered low.

-18.46

How Well Does AVCN.TO Make Money?

Net Profit Margin

For every $100 in sales, Avicanna Inc. keeps $-7.37 as profit after all expenses.

-7.37%

Operating Margin

Core operations generate -12.55 in profit for every $100 in revenue, before interest and taxes.

-12.55%

ROE

Management delivers $-68.32 in profit for every $100 of shareholder equity.

-68.32%

ROA

Avicanna Inc. generates $-8.87 in profit for every $100 in assets, demonstrating efficient asset deployment.

-8.87%

Following the Money - Real Cash Generation

Operating Cash Flow

Avicanna Inc. generates limited operating cash flow of $-1.35M, signaling weaker underlying cash strength.

$-1.35M

Free Cash Flow

Avicanna Inc. generates weak or negative free cash flow of $-1.96M, restricting financial flexibility.

$-1.96M

FCF Per Share

Each share generates $-0.02 in free cash annually.

$-0.02

FCF Yield

AVCN.TO converts -9.48% of its market value into free cash.

-9.48%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-9.16

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.84

vs 25 benchmark

P/B Ratio

Price to book value ratio

5.53

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.74

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.90

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.68

vs 25 benchmark

ROA

Return on assets percentage

-0.09

vs 25 benchmark

ROCE

Return on capital employed

-0.26

vs 25 benchmark

How AVCN.TO Stacks Against Its Sector Peers

MetricAVCN.TO ValueSector AveragePerformance
P/E Ratio-9.1628.31 Better (Cheaper)
ROE-68.32%699.00% Weak
Net Margin-7.37%-131318.00% (disorted) Weak
Debt/Equity0.000.34 Strong (Low Leverage)
Current Ratio0.902775.16 Weak Liquidity
ROA-8.87%-14513.00% (disorted) Weak

AVCN.TO outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Avicanna Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

2933.52%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

96.73%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

97.37%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ